---
aliases: [GILD, Gilead Sciences]
---
#actor #biotech #hiv #oncology #usa #public

**Gilead** — HIV franchise leader. Biktarvy dominance. $28B+ revenue. Oncology growing with Trodelvy.

---

## Why Gilead matters

| Metric | Value |
|--------|-------|
| Ticker | GILD ([[Nasdaq]]) |
| 2025 revenue guidance | **$28.2-28.6B** |
| HIV revenue (9M 2025) | $15.0B (+6% YoY) |
| Biktarvy | $3.5B/quarter |

---

## HIV franchise

| Product | Q2 2025 | Growth |
|---------|---------|--------|
| **Biktarvy** | $3.5B | +9% YoY |
| Descovy | $653M | +35% YoY |
| Other HIV | ~$900M | Mixed |

**Dominance:** HIV is 75%+ of Gilead revenue.

**IRA headwind:** Medicare Part D redesign reducing 2025 revenue by ~$1.1B (~$900M from HIV).

---

## Oncology portfolio

| Product | Q2 2025 | Notes |
|---------|---------|-------|
| Trodelvy | $364M | +14% YoY, breast cancer |
| Cell therapies | Declining | Competition |

**9M 2025 oncology:** $2.4B (-2% YoY).

---

## Pipeline

| Asset | Indication | Status |
|-------|------------|--------|
| Lenacapavir | HIV prevention | Long-acting injectable |
| Trodelvy | Label expansion | Growing indications |
| Cell therapy | CAR-T | Competitive pressure |

**Lenacapavir:** Potential game-changer for HIV prevention (twice-yearly dosing).

---

## Financial performance

| Metric | 2025E |
|--------|-------|
| Product sales | $28.2-28.6B |
| HIV growth | +6% (underlying) |
| Oncology | Flat to declining |
| Margin | Stable |

---

## Challenges

| Issue | Impact |
|-------|--------|
| IRA pricing | ~$1.1B revenue headwind |
| Oncology competition | Cell therapy pressure |
| HIV maturity | Limited growth upside |
| Pipeline gaps | Needs new growth drivers |

---

## TCJA repatriation (2018)

Gilead repatriated significant overseas cash under the [[Tax Cuts and Jobs Act]] one-time tax holiday. Deployed into buybacks and dividends.

---

## Investment case

**Bull:**
- HIV franchise durability
- Biktarvy dominance
- Lenacapavir catalyst
- Strong cash generation

**Bear:**
- IRA pricing pressure
- Oncology struggles
- HIV market mature
- Limited pipeline visibility

---

## Quick stats

| Metric | Value |
|--------|-------|
| Ticker | GILD |
| Exchange | [[Nasdaq]] |
| Revenue | ~$28B |
| Focus | HIV, oncology |

---

## Related

- [[Biopharma]] — sector
- [[Tax Cuts and Jobs Act]] — repatriation (2018)

---

## Sources

- [Gilead Q2 2025 results](https://www.gilead.com/news/news-details/2025/gilead-sciences-announces-second-quarter-2025-financial-results)
- [BioPharma Dive](https://www.biopharmadive.com/news/gilead-first-quarter-earnings-hiv-oncology/746375/)

*Created 2026-01-09*
